A Phase 1, single-center, nonrandomized, open-label, active-controlled, 2-period, 2-treatment evaluation of multiple-dose topical administration of FMX-101 minocycline foam 4%, compared to oral administration of Solodyn (minocycline HCl) extended-release tablets in subjects with moderate-to-severe facial acne vulgaris and acne: Bridging/Maximal Use (MUSE) trial

Trial Profile

A Phase 1, single-center, nonrandomized, open-label, active-controlled, 2-period, 2-treatment evaluation of multiple-dose topical administration of FMX-101 minocycline foam 4%, compared to oral administration of Solodyn (minocycline HCl) extended-release tablets in subjects with moderate-to-severe facial acne vulgaris and acne: Bridging/Maximal Use (MUSE) trial

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Minocycline (Primary)
  • Indications Acne
  • Focus Pharmacokinetics
  • Acronyms MUSE
  • Most Recent Events

    • 07 Jan 2016 Status changed from active, no longer recruiting to completed, as published in the Media Release
    • 07 Jan 2016 Results published in the Media Release
    • 11 Nov 2015 According to Foamix media release, results are expected to be released during Q4, 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top